PRINCETON, NJ--(MARKET WIRE)--Jun 4, 2007 -- Atlan International Holdings Corp. (Frankfurt:QV8.F - News) (Other OTC:ATLI.PK - News), a company which is a global development, marketing, sales and acquisition firm with subsidiaries that develop, design and market pharmaceuticals, biotechnology, bio-pharmaceuticals, alternative medicines & nutraceuticals, announced today that its subsidiary Atlan Pharma Inc. completed and approved the developmental plan for their first pharmaceutical product, AT 103-ED, that is being developed for an indication of erectile dysfunction. The company is in the process of selecting contract houses for various activities related to this product development. The first to be initiated is the formulation development that will utilize the platform technology licensed by Atlan for which the US and PCT patents are pending. Later in 2007, the company is planning to have a meeting with the FDA to discuss the agency’s requirements for IND submission and then clinical development of the product.
